RxDoctor Payments Data

Stacey Wheatley

Nurse Practitioner · Sherman, TXNPI 1629519368

Payments from drug & device makers

$5,018in general payments, 2019–2025

Across 214 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$2K
  • Johnson & Johnson$223
  • Merck$208
  • Organon$116
  • Janssen Products, LP$89
  • plus $162 from 5 others

What the payments were for

  • Food & beverage$4,92998%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company123$2,650
Gilead52$1,570
Johnson & Johnson(2 entities)14$223
Merck11$208
Organon6$116
Janssen Products, LP1$89
CSL Behring3$70
EMD Serono, Inc.1$27
Biogen1$25
Abbott1$24
Vertex1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,018 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$3,211
Medicare patients
14
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine71$201,481
JulucaDolutegravir/Rilpivirine12$42,367
TriumeqAbacavir/Dolutegravir/Lamivudi11$38,708
XifaxanRifaximin11$36,128
PrezcobixDarunavir/Cobicistat11$24,724
TivicayDolutegravir Sodium11$22,689
TrulicityDulaglutide13$12,780
OzempicSemaglutide11$10,715
LinzessLinaclotide19$10,012
SavellaMilnacipran Hcl12$5,888
Breo ElliptaFluticasone/Vilanterol11$4,510
Varenicline Tartrate12$2,869
ValacyclovirValacyclovir Hcl32$1,008
Entecavir11$482
Albuterol Sulfate HfaAlbuterol Sulfate12$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Triumeq, Tivicay$2,650$305,244105 claims
Johnson & JohnsonPrezcobix$223$24,72411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →